EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced the granting of non-statutory stock options to four new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan. These grants, approved by the Compensation Committee, are in accordance with NASDAQ Listing Rule 5635(c)(4). The stock options, totaling 69,000 shares of EyePoint Pharmaceuticals common stock, were granted on October 15, 2024, with an exercise price of $9.88 per share.
The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in equal monthly installments over the following three years. Vesting is subject to continued service with the company.
EyePoint Pharmaceuticals (NASDAQ: EYPT) ha annunciato l'assegnazione di opzioni su azioni non statutarie a quattro nuovi dipendenti come premi di induzione al di fuori del Piano di Incentivi a Lungo Termine 2023 della Società. Questi assegnazioni, approvate dal Comitato per la Retribuzione, sono in conformità con la Regola di Quotazione NASDAQ 5635(c)(4). Le opzioni su azioni, per un totale di 69.000 azioni di azioni ordinarie di EyePoint Pharmaceuticals, sono state assegnate il 15 ottobre 2024, con un prezzo di esercizio di $9,88 per azione.
Le opzioni hanno un termine di dieci anni e maturano nel corso di quattro anni, con il 25% che matura al primo anniversario e il resto che matura in rate mensili uguali nei tre anni successivi. La maturazione è soggetta a un servizio continuato con l'azienda.
EyePoint Pharmaceuticals (NASDAQ: EYPT) ha anunciado la concesión de opciones sobre acciones no estatutarias a cuatro nuevos empleados como premios inducidos fuera del Plan de Incentivos a Largo Plazo 2023 de la Compañía. Estas concesiones, aprobadas por el Comité de Compensación, están de acuerdo con la Regla de Listado NASDAQ 5635(c)(4). Las opciones sobre acciones, que totalizan 69,000 acciones de acciones ordinarias de EyePoint Pharmaceuticals, fueron concedidas el 15 de octubre de 2024, con un precio de ejercicio de $9.88 por acción.
Las opciones tienen un plazo de diez años y se devengan durante cuatro años, con el 25% devengando en el primer aniversario y el resto devengando en cuotas mensuales iguales durante los tres años siguientes. El devengamiento está sujeto a la continuidad del servicio con la empresa.
EyePoint Pharmaceuticals (NASDAQ: EYPT)는 네 명의 새로운 직원에게 2023년 장기 인센티브 계획 외부에서 유인 보상으로 비법정 주식 옵션을 부여한다고 발표했습니다. 이 부여는 보상위원회의 승인을 받았으며 NASDAQ 상장 규칙 5635(c)(4)에 따릅니다. 주식 옵션은 EyePoint Pharmaceuticals의 보통주 69,000주에 해당하며, 2024년 10월 15일에 부여되었고, 행사 가격은 주당 $9.88입니다.
옵션의 유효 기간은 10년이며, 4년에 걸쳐 변동하며, 첫 번째 기념일에 25%가 변동되고 나머지는 다음 3년 동안 매달 동일한 금액으로 변동합니다. 변동은 회사에서의 지속적인 서비스에 따라 다릅니다.
EyePoint Pharmaceuticals (NASDAQ: EYPT) a annoncé l'octroi d'options d'achat d'actions non statutaires à quatre nouveaux employés en tant que récompenses incitatives en dehors du Plan d'Incentive à Long Terme 2023 de l'Entreprise. Ces attributions, approuvées par le Comité de Rémunération, sont conformes à la règle de cotation NASDAQ 5635(c)(4). Les options d'achat d'actions, totalisant 69 000 actions ordinaires d'EyePoint Pharmaceuticals, ont été attribuées le 15 octobre 2024, avec un prix d'exercice de 9,88 $ par action.
Les options ont une durée de dix ans et se libèrent sur quatre ans, avec 25 % se libérant au premier anniversaire et le reste se libérant en mensualités égales sur les trois années suivantes. La libération est soumise à une continuité de service avec l'entreprise.
EyePoint Pharmaceuticals (NASDAQ: EYPT) hat die Gewährung von nicht-statuarischen Aktienoptionen an vier neue Mitarbeiter als Anreizvergaben außerhalb des langfristigen Anreizplans 2023 des Unternehmens angekündigt. Diese Gewährungen wurden vom Vergütungsausschuss genehmigt und entsprechen der NASDAQ-Listing-Regel 5635(c)(4). Die Aktienoptionen, die insgesamt 69.000 Aktien des Stammkapitals von EyePoint Pharmaceuticals betragen, wurden am 15. Oktober 2024 gewährt, mit einem Ausübungspreis von 9,88 $ pro Aktie.
Die Optionen haben eine Laufzeit von zehn Jahren und verfallen über einen Zeitraum von vier Jahren, wobei 25 % am ersten Jahrestag verfallen und der Rest in gleichen monatlichen Raten über die folgenden drei Jahre verfallen. Das Verfallen ist an die Fortsetzung des Dienstes im Unternehmen gebunden.
- Granting of stock options may help attract and retain talented employees
- The company is expanding its workforce with four new hires
- Potential dilution of existing shareholders' equity due to the issuance of new stock options
WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 69,000 shares of EyePoint Pharmaceuticals common stock to four new employees. The stock options were granted on October 15, 2024. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. DURAVYU is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and diabetic macular edema (DME). EyePoint expects to randomize patients for inclusion in pivotal Phase 3 clinical trials in wet AMD in 2024.
Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
For EyePoint Pharmaceuticals:
Investors:
Christina Tartaglia
Precision AQ (formerly Stern IR)
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
How many shares of stock options did EyePoint Pharmaceuticals (EYPT) grant to new employees?
What is the exercise price of the stock options granted by EyePoint Pharmaceuticals (EYPT) on October 15, 2024?
What is the vesting schedule for the stock options granted by EyePoint Pharmaceuticals (EYPT)?
Under which NASDAQ rule did EyePoint Pharmaceuticals (EYPT) grant these inducement awards?
